Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersMedical Oncology Physician in Boston, MA
NPI: 1144495375Primary Practice Location
BOSTON MEDICAL CENTER
1 Boston Medical Ctr Pl, Boston, MA
Primary Employer
Boston University Internal Medicine Associates
bmc.org
HQ Phone
Get M.D. Peter's Phone Numberphone_androidMobile
Get M.D. Peter's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 37 | 86 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 27 | 52 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 14 | 14 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 12 | 28 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 11 | 13 |
Authors: Umit Tapan, Zoe Mackay, Laura Amin, Mohini Patel, Chinmay Jani
Journal: Oncologist
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, BIOLOGICAL: Nivolumab, DRUG: Cisplatin, DRUG: Etoposide
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Nivolumab, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, PROCEDURE: Echocardiography Test, OTHER: Observation Activity
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, DRUG: Sunitinib Malate, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, DRUG: Osimertinib, PROCEDURE: Biospecimen Collection, DRUG: Dabrafenib, DRUG: Crizotinib, DRUG: Sapanisertib, DRUG: Taselisib, PROCEDURE: Computed Tomography, BIOLOGICAL: Trastuzumab, DRUG: Trametinib, PROCEDURE: Multigated Acquisition Scan, DRUG: Palbociclib, DRUG: Afatinib, DRUG: Ulixertinib, OTHER: Cytology Specimen Collection Procedure, DRUG: Dasatinib, DRUG: Vismodegib, DRUG: Afatinib Dimaleate, DRUG: Adavosertib, PROCEDURE: Biopsy Procedure, DRUG: Defactinib, PROCEDURE: Radionuclide Imaging, BIOLOGICAL: Trastuzumab Emtansine, DRUG: Copanlisib, PROCEDURE: Echocardiography Test, DRUG: PI3K-beta Inhibitor GSK2636771, DRUG: Larotrectinib, BIOLOGICAL: Relatlimab, DRUG: Copanlisib Hydrochloride, DRUG: Capivasertib, DRUG: Erdafitinib, DRUG: Larotrectinib Sulfate, DRUG: Binimetinib, BIOLOGICAL: Pertuzumab, DRUG: Ipatasertib, DRUG: Dabrafenib Mesylate, DRUG: Defactinib Hydrochloride, DRUG: Fexagratinib, PROCEDURE: Radiologic Examination
